Lack of FGF23 response to acute changes in serum calcium and PTH in humans

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages E1951-E1956

  Wesseling Perry, Katherine ^a   Wang, Hejing ^a   Elashoff, Robert ^a   Gales, Barbara ^a   Jüppner, Harald ^b   Salusky, Isidro B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; CITRATE SODIUM; FIBROBLAST GROWTH FACTOR 23; GLUCONATE CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; 1,25-DIHYDROXYVITAMIN D; CITRIC ACID; FIBROBLAST GROWTH FACTOR; VITAMIN D;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CARBOXY TERMINAL SEQUENCE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; FEEDBACK SYSTEM; FEMALE; KIDNEY FAILURE, CHRONIC; MALE; METABOLISM; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; YOUNG ADULT;

ADOLESCENT; CALCIUM; CITRATES; FEEDBACK, PHYSIOLOGICAL; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; VITAMIN D; YOUNG ADULT;

EID: 84907637553     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2125     Document Type: Article

References (21)

1. Naveh-Many T, Bell O, Silver J, Kilav R. Cis and trans acting factors in the regulation of parathyroid hormone (PTH) mRNA stability by calcium and phosphate. FEBS Lett. 2002;529:60-64.
2. Portale AA, Booth BE, Halloran BP, Morris RC Jr. Effect of dietary phosphorus on circulating concentrations of 1, 25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest. 1984;73:1580-1589.
3. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006;91:3144-3149.
4. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1, 25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005;146:5358-5364.
5. Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem. 1998;273:5253-5259.
6. Wetmore JB, Santos PW, Mahnken JD, et al. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. J Clin Endocrinol Metab. 2011;96:E57-E64.
7. Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 2004;65:1943-1946.
8. Rodriguez-Ortiz ME, Lopez I, Muñoz-Castañeda JR, et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol. 2012;23:1190-1197.
9. Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor in dependent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005;289:F1088-F1095.
10. Cancela AL, Oliveira RB, Graciolli FG, et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract. 2011;117:c74-c82.
11. David V, Dai B, Martin A, Huang J, Han X, Quarles LD. Calcium regulates FGF-23 expression in bone. Endocrinology. 2013;154:4469-4482.
12. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299:F882-F889.
13. Wesseling-Perry K, Harkins GC, Wang HJ, et al. The calcemic response to continuous parathyroid hormone (PTH) (1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH (7-84). J Clin Endocrinol Metab. 2010;95:2772-2780.
14. Burnett-Bowie SM, Henao MP, Dere ME, Lee H, Leder BZ. Effects of hPTH (1-34) infusion on circulating serum phosphate, 1, 25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res. 2009;24:1681-1685.
15. Takahashi H, Komaba H, Takahashi Y, et al. Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Endocrinol Metab. 2014;99:E652-E658.
16. Lim K, Lu TS, Molostvov G, et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation. 2012;125:2243-2255.
17. Ramirez JA, Goodman WG, Gornbein J, et al. Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab. 1993;76:1489-1494.
18. Sanchez CP, Goodman WG, Ramirez JA, et al. Calcium-regulated parathyroid hormone secretion in adynamic renal osteodystrophy. Kidney Int. 1995;48:838-843.
19. Kifor O, Moore FD Jr, Wang P, et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:1598-1606.
20. Slatopolsky E, Finch J, Clay P, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000;58:753-761.
21. Gutiérrez OM, Smith KT, Barchi-Chung A, Patel NM, Isakova T, Wolf M. (1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. Clin J Am Soc Nephrol. 2012;7:139-145.